Indian pharmaceutical company Strides Arcolab has entered
into a licensing agreement with US-based Gilead Sciences to manufacture and
distribute latter's low-cost HIV drug, Tenofovir Alafenamide (TAF), in
developing countries.
In a BSE filing, Strides Arcolab said, "It has entered
into a licensing agreement with Gilead Sciences, Inc under which Gilead has
extended non-exclusive rights to Strides to manufacture and distribute
Tenofovir Alafenamide (TAF), both as a single agent product and in combination
with other drugs."
Drug Resistance - Antibiotic Resistance
Drug resistance is often a problem in malaria, tuberculosis, HIV, sexually transmitted diseases and hospital acquired diseases. Judicious use of antibiotics can control the problem.
Advertisement
Strides said that the license being granted to it extends to 112 countries.
"Strides will receive technology transfer from Gilead,
enabling Strides to manufacture low cost versions of TAF for developing countries,"
the company stated.
TAF is an investigational product in the US and have not yet been determined safe and efficacious in humans.
Source: Medindia
TAF is an investigational product in the US and have not yet been determined safe and efficacious in humans.
Source: Medindia
Bone Metastases in Prostate Cancer Blocked by HIV Drug
While most men with prostate cancer can be successfully treated, when the disease metastasizes to the bone, it eventually becomes lethal.
Advertisement
 Vision Loss can be Stopped With Help of HIV DrugsStudy has revealed that drugs used for HIV virus and AIDS treatment can help fight loss of vision. | Advertisement
|
Altered Milk Protein can Deliver HIV Drug to Infants and Young Children
A novel method of altering a protein in milk to bind with an antiretroviral drug promises to greatly improve treatment for infants and young children suffering from HIV/AIDS.
Advertisement
Recommended Reading
Latest AIDS/HIV News
A new study has found that the co-localization of tuberculosis disease and HIV in lymphatic tissues leads to the emergence of potent HIV antibodies.
Specific antiviral drug that is widely used to treat smallpox patients since last summer's outbreak is found to produce similar outcomes regardless of the patient's HIV status.
In susceptible communities because of poverty, and racism, the effects of inadequate STI and HIV screening may be more profound.
In India, annual HIV infections and AIDS-related deaths continue to drop. Between 2010 and 2021, new HIV infections dropped by 46%.
Globally, all countries have promised to end AIDS by 2030, for which it is essential to safeguard individuals living with HIV to complete HIV care services.